Molecular Devices and ForteBio combine to create new Biologics Solutions business unit to drive integrated workflow offerings for drug discovery and development

Apr 26, 2018

San Jose, CA, April 26, 2018 — Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the combination of its Biologics BioTherapeutics division with Pall Corporation’s ForteBio division—a world leader in label-free analysis for biomolecular detection and characterization that accelerates drug discovery and development.

The combined entity, called Biologics Solutions, will operate as a business unit within Molecular Devices and will involve the transition of all personnel and technology from Pall ForteBio to Molecular Devices, both operating companies of Danaher, a global science and technology innovator.

“We are bringing together the best in protein analysis and characterization, and the best in clone selection as a unified team to provide integrated workflow solutions for cell line development in biologics process development,” said Greg Milosevich, President of Molecular Devices. “By combining Pall’s ForteBio business with Molecular Devices Biologics BioTherapeutics division, we will offer streamlined and responsive support for improved customer confidence and save precious time in customer research, discovery and drug development.”

The increasing number of approved biologics and biosimilars in recent years has fueled the demand for technologies that enhance productivity in drug discovery and development. Currently, large numbers of hybridoma and cell clones have to be screened in early development stages for a number of product characteristics to select lead molecules and identify rare stable high producer clones. By integrating the teams that offer protein analysis technologies at ForteBio and clone picking technologies at Molecular Devices, the Biologics Solutions unit will improve the speed and efficiency in selecting lead molecules, generating highly productive cell lines and developing processes for manufacturing. The business unit will launch a newly combined ‘go-to-market’ team to expand its reach and service to its customers, improve customer intimacy, and offer truly integrated workflow solutions for therapeutic drug discovery and development.

Beginning in July 2018, the Biologics Solutions business unit will manage both the ForteBio and Biologics BioTherapeutics product portfolios under the newly created biologics brand within Molecular Devices.

 

About Molecular Devices

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.  

For more information, please visit www.moleculardevices.com